Company file Nº 875 / 1000 · Series A · United States · updated 14 Sep 2026
Shinobi Therapeutics
GTM score
17.4
In its stage
247th of 250 Series A
Ranked against 1000 companies indexed as at 14 Sep 2026. The index grows every month, so a rank can move without a company changing.
What they do
Immune-evasive iPSC therapies for cancer and other diseases
The pillar map
exit criteria metexit criteria partly metexit criteria not metno public signal found
The real colors on all 16 pillars, with each pillar's score, free with an email address.
Our read
We read every map the same way: where the engine is strong, where it's stuck, and what matters most next. Our read on Shinobi Therapeutics: our read, unlocks with email
What the full report adds
GTM score over time
Think we got Shinobi Therapeutics wrong? and we will take another look. How we score →